Copyright
©The Author(s) 2016.
World J Gastrointest Pathophysiol. Feb 15, 2016; 7(1): 117-124
Published online Feb 15, 2016. doi: 10.4291/wjgp.v7.i1.117
Published online Feb 15, 2016. doi: 10.4291/wjgp.v7.i1.117
Table 1 Duodenal neuroendocrine tumors treatment
| Duodenal NETs – surgical treatment | |
| ≤ 1 cm | Local ressection (if possible) |
| ≥ 2 cm OR lymph nodes metastasis | Surgical ressection |
| Potentially resectable hepatic metastases without distant metastases and no other significant comorbility | Palliative surgery |
| Duodenal NETs – farmacological treatment | |
| Functional duodenal NETs | Hormone suppression treatment |
| Well-differentiated NETs | Systemic chemotherapy if advanced metastatic disease |
| Poorly differentiated tumors | Combination chemotherapy – variable duration disease remission |
| mTOR, tyrosine kinase and VEGF inhibitors – phase 3 trials with promising results | |
| Metastatic or inoperable disease | Peptide receptor radionuclide therapy |
| When all other treatment options fail | |
| If positive octreoscan | |
Table 2 Jejunal and ileal neuroendocrine tumors treatment
| Jejunal and ileal NETs – surgical treatment | |
| Without metastasis, all sizes | Surgical resection with wide lymphadenectomy + search for other lesions |
| With liver metastases | Attempt curative surgery; intraoperative ultrasonography should be performed for detection of all liver metastases |
| If patient not suitable for curative resection, palliative surgery should be considered to prevent complications attributable to the tumor mass | |
| Jejunal and ileal NETs – farmacological treatment | |
| Functional jejunal-ileal NETs | 1st line: Somatostatin analogs (symptomatic treatment and tumor growth stabilization) |
| 2nd line: Interferon-α | |
| Well-differentiated NETs | Systemic chemotherapy not recommended |
| Poorly differentiated tumors | Combination chemotherapy – variable duration disease remission |
| mTOR, tyrosine kinase and VEGF inhibitors – phase 3 trials with promising results | |
| Metastatic or inoperable disease | Peptide receptor radionuclide therapy |
| When all other treatment options fail | |
| If positive Octreoscan | |
- Citation: Xavier S, Rosa B, Cotter J. Small bowel neuroendocrine tumors: From pathophysiology to clinical approach. World J Gastrointest Pathophysiol 2016; 7(1): 117-124
- URL: https://www.wjgnet.com/2150-5330/full/v7/i1/117.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v7.i1.117
